Hoth Therapeutics Inc (HOTH)

NASDAQ
1.34
-0.03(-2.19%)
  • Volume:
    418,787
  • Bid/Ask:
    1.33/1.34
  • Day's Range:
    1.33 - 1.37

HOTH Overview

Prev. Close
1.37
Day's Range
1.33 - 1.37
Revenue
-
Open
1.35
52 wk Range
1.27 - 4.95
EPS
-0.6
Volume
418,787
Market Cap
32.7M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
4,651,580
P/E Ratio
-
Beta
-
1-Year Change
-65.05%
Shares Outstanding
23,871,671
Next Earnings Date
May 19, 2021
What is your sentiment on Hoth Therapeutics Inc?
or
Vote to see community's results!

Hoth Therapeutics Inc News

Hoth Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Hoth Therapeutics Inc Company Profile

Hoth Therapeutics Inc Company Profile

Employees
3

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.

Read More
  • 🚀🚀🚀
    0
    • Buy, TP 5-6
      1
      • Jan 28, 2021, 08:02 ET Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic
        1
        • u're also here?
          0
      • Hoth Therapeutics Announces Production of HT-001 for Cancer TreatmentThu, December 31, 2020, 8:01 AM EST·4 min readHOTH+44.51%NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
        0
        • Long downfall/ stagnation then sudden activity indicates likely surge in growth for a term. News also indicates a keeper (look into partnerships).
          2
          • Long downfall/ stagnation then sudden activity indicates likely surge in growth for a term. News also indicates a keeper (look into partnerships).
            0
            • Wow! Anyone know the reason behind this surge? Cheers.
              0
              • Covid-19 precention halovax agreement with voltron.
                1
            • Wait again for it
              0
              • finally
                0
                • ?
                  0
                • 👍🏻 of 👎🏻
                  1
              • stock has good news...must move higher...
                1
                • in at 5.97
                  1
                  • in at 5.97
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.